BioLineRx out-licenses HCV compound to Jiangsu Chia-Tai

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) granted Jiangsu Chia-Tai Tianqing Pharmaceutical Co. Ltd. (Lianyungang, China) exclusive Chinese rights to develop and commercialize HCV compound BL-8030. BioLineRx will retain rights in the rest of the world to the oral selective HCV NS3/4A inhibitor, which is in preclinical development to treat HCV. BioLineRx will receive up to $30 million in an upfront license fee and milestones, and is also eligible for high single-digit royalties. BioLineRx, which could not be reached for details, in-licensed the compound from Genoscience (Marseille, France) and RFS Pharma LLC (Tucker, Georgia) in February 2012 (see BioCentury Extra, Feb. 6, 2012). ...